---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-009831"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:12:42.442404+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences reports FY2023 net loss of $42.2M; plans $60M rights offering

## Summary
- GAAP net loss FY 2023 ($42.2M) vs ($58.5M) in 2022; Q4 net loss ($11.9M) vs ($9.2M) prior year.
- Cash and equivalents $44.4M at Dec 31, 2023, down from $61.1M a year earlier.
- FDA 510(k) clearance for CellFX nsPFA Percutaneous Electrode for non-cardiac soft tissue ablation.
- Rights offering of up to $60M in Units (share + warrants) to existing holders; record date in April.
- Chairman Robert Duggan supports and intends to participate in rights offering on same terms.

## SEC filing metadata
- accession: 0001437749-24-009831
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774924009831/0001437749-24-009831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774924009831/plse20240327_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-009831
- JSON: https://secwatch.observer/filing/0001437749-24-009831.json
- Plain text: https://secwatch.observer/filing/0001437749-24-009831.txt

## Key facts
- Earnings Releases
  PULSE BIOSCIENCES, INC. reported the fiscal quarter and full year ended December 31, 2023 results: net income ($11.9) million.
  - Period: the fiscal quarter and full year ended December 31, 2023
  - Net income: ($11.9) million
  - Result: reported results
  source text: On March 28, 2024, Pulse Biosciences, Inc. (the “Company”) announced its financial and operational results for the fiscal quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774924009831/0001437749-24-009831-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.